Navigation Links
UAlberta researchers uncover why combination drug treatment ineffective in cancer clinical trials
Date:12/5/2013

Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

Faculty of Medicine & Dentistry researcher Michael Sawyer and his colleagues, including first author Vijaya Damaraju, recently published their findings in the peer-reviewed journal, Clinical Cancer Research.

In the '80s and '90s, cancer research focused on finding out which proteins "drove" cancers. New drugs targeting these proteins worked well by themselves, and some in the field believed combining the new drugs with the older chemotherapy drugs would work better than either drug by itself.

"So the pharmaceutical industry developed a combination of drugs in which we thought we were giving two drugs at once, but in actual fact the one drug we were giving was completely blocking the actions of the other drug," said Sawyer, who works in the Faculty's Department of Oncology.

"The old chemotherapy drugs required special proteins to get inside of cells to work. What our team discovered is that the new chemotherapy drugs prevented these proteins from carrying the old chemotherapy drugs into the cell. No one was able to figure out why this combination of drugs didn't work, but now we have discovered what went wrong." Sawyer says the findings will guide oncologists about how cancer drugs should be combined, or whether certain drugs should be combined at all.

"This will save us from doing millions of dollars in clinical trials that have no chance of working out. These findings show oncologists we have to be careful about which drugs should be combined. You have to think about how they actually work, especially in ways which no one understood before.

"Our research was actually like peeling an onion. Once we figured out the answer to one question, then other things the drugs did make more sense. Ultimately, the findings mean we'll be able to design better combination drug therapies. We'll know which drugs to combine, and when and how drugs can be combined. This will require more precise scheduling and dosing than what we've done to date."

He stressed the only patients impacted were those in clinical trials the combination drug therapy had not yet become common clinical practice because it wasn't working the way oncologists had hoped. And for those patients who took part in the clinical trials, the one chemotherapy drug was still very effective so those patients still received excellent care and drugs that properly targeted their cancers.

Sawyer and his team are continuing their research in this area. Their research was funded by the former Alberta Cancer Board, the Alberta Cancer Foundation and Alberta Innovates Health Solutions.


'/>"/>

Contact: Raquel Maurier
rmaurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Related medicine news :

1. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
2. UAlberta medical researchers make key discovery in fight against Alzheimers disease
3. UAlberta medical researchers discover new potential chemotherapy
4. Alternative medicine use high amoung children with chronic conditions: UAlberta medical research
5. Alternative medicine use high among children with chronic conditions: UAlberta medical research
6. New UAlberta research shows commonly prescribed medications could have adverse effects
7. UAlberta researcher pinpoints prescription for successful Primary Care Networks
8. Low birth weight could be a risk factor for age-related vision loss: UAlberta medical research
9. Music decreases perceived pain for kids in pediatric ER: UAlberta medical research
10. NIH awards $20 million over 5 years to train next generation of global health researchers
11. Researchers develop a new cell and animal model of inflammatory breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: